SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic.

PURPOSE To analyze the prevalence of SARS-CoV-2 infection in patients with cancer in hospital care after implementation of institutional and governmental safety measurements. METHODS Patients with cancer routinely tested for SARS-CoV-2 RNA by nasal swab and real-time polymerase chain reaction between March 21 and May 4, 2020, were included. The results of this cancer cohort were statistically compared with the SARS-CoV-2 prevalence in the Austrian population as determined by a representative nationwide random sample study (control cohort 1) and a cohort of patients without cancer presenting to our hospital (control cohort 2). RESULTS A total of 1,688 SARS-CoV-2 tests in 1,016 consecutive patients with cancer were performed. A total of 270 of 1,016 (26.6%) of the patients were undergoing active anticancer treatment in a neoadjuvant/adjuvant and 560 of 1,016 (55.1%) in a palliative setting. A total of 53 of 1,016 (5.2%) patients self-reported symptoms potentially associated with COVID-19. In 4 of 1,016 (0.4%) patients, SARS-CoV-2 was detected. At the time of testing at our department, all four SARS-CoV-2-positive patients were asymptomatic, and two of them had recovered from symptomatic COVID-19. Viral clearance was achieved in three of the four patients 14-56 days after testing positive. The estimated odds ratio of SARS-CoV-2 prevalence between the cancer cohort and control cohort 1 was 1.013 (95% CI, 0.209 to 4.272; P = 1), and between control cohort 2 and the cancer cohort it was 18.333 (95% CI, 6.056 to 74.157). CONCLUSION Our data indicate that continuation of active anticancer therapy and follow-up visits in a large tertiary care hospital are feasible and safe after implementation of strict population-wide and institutional safety measures during the current COVID-19 pandemic. Routine SARS-CoV-2 testing of patients with cancer seems advisable to detect asymptomatic virus carriers and avoid uncontrolled viral spread.

[1]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[2]  A. Banerjee,et al.  Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency , 2020, medRxiv.

[3]  Zhiquan Hu,et al.  Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[4]  Leora I. Horwitz,et al.  Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.

[5]  H. Salihu,et al.  COVID-19 Pandemic: Marked Global Disparities in Fatalities According to Geographic Location and Universal Health Care , 2020, International journal of MCH and AIDS.

[6]  A. Giacomelli,et al.  30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study , 2020, Pharmacological Research.

[7]  Jian Wang,et al.  Epidemiological and clinical features of asymptomatic patients with SARS‐CoV‐2 infection , 2020, Journal of medical virology.

[8]  Gholamreza Farnoosh,et al.  Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study , 2020, Journal of Clinical Virology.

[9]  S. Cannistra,et al.  Challenges Faced by Medical Journals During the COVID-19 Pandemic. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Bingliang Zeng,et al.  Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? , 2020, European Journal of Radiology.

[11]  M. Chua,et al.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China , 2020, JAMA oncology.

[12]  Li Zhang,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[13]  Yu Xiao,et al.  Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[15]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[16]  E. Brunner,et al.  Distributions and Effects , 2018 .

[17]  A. Berger,et al.  Verification and validation of diagnostic laboratory tests in clinical virology. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  A. Agresti,et al.  Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions , 1998 .